HIV Clinical Trials Market Is Projected To Grow Robustly

HIV Clinical Trials Market Summary

The global HIV clinical trials market size was estimated at USD 1.56 billion in 2024 and is projected to reach USD 2.11 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.8% from 2025 to 2030. The market holds substantial growth potential, largely driven by an increasing number of drug approvals for HIV treatment, higher investment in research and development by pharmaceutical and biotechnology companies, and the steadily growing incidence of HIV infections globally. These factors are collectively pushing forward the need for more efficient, accessible, and targeted treatment options.

In addition to facilitating drug approvals, clinical trials are also vital for advancing innovative therapies, including precision medicine and novel HIV vaccines. These initiatives are not only improving clinical outcomes for patients but are also helping to lower global infection rates. The HIV clinical trial ecosystem is undergoing continuous transformation as stakeholders strive to address multiple unmet needs, such as treatment adherence and drug resistance. The growing interest in long-acting injectables, potential curative therapies, and inclusive trials that serve diverse global populations further amplifies market momentum.

A key focus area is improving access to treatment and ensuring broader participation in trials from underrepresented regions and communities. This strategic expansion aligns with global health goals aimed at ending the HIV epidemic. Increasing government support and favorable regulatory frameworks in both developed and emerging countries have also strengthened the clinical trial infrastructure, contributing to the market’s upward trajectory. These advancements are creating a favorable environment for sponsors and researchers to accelerate drug development while ensuring safety and efficacy.

Key Market Trends & Insights

• By trial phase, the phase III segment led the HIV clinical trials market in 2024, accounting for a revenue share of 30.0%. Phase III trials are critical in evaluating the safety and efficacy of drugs at a larger scale before regulatory approval. These trials often involve diverse patient populations and aim to establish definitive evidence on therapeutic effectiveness, ultimately supporting marketing authorization.
• The interventional studies segment was the dominant study design type in 2024, capturing a revenue share of 69.8%. This segment's growth can be attributed to its ability to provide actionable outcomes, cost-effectiveness, and its rising application in preventive HIV treatments. Interventional trials help identify benefits and limitations of treatment strategies early on and play a key role in shaping clinical guidelines and public health policies.
• In terms of sponsor type, pharmaceutical and biopharmaceutical companies led the market in 2024. This dominance can be traced to increased R&D investments, rising demand for advanced and effective treatment options, and the introduction of new drugs targeting both prevention and management of HIV. These companies are also exploring partnerships and licensing deals to accelerate clinical development pipelines.
• Regionally, North America emerged as the largest market in 2024, accounting for a revenue share of 47.3%. This is mainly due to a high volume of HIV clinical trials conducted in the region, along with robust government support, well-established infrastructure, and strong research capabilities. Increased collaboration between public institutions and private sector players further bolsters the region’s leadership in the HIV clinical research landscape.
• Within North America, the United States dominates the regional market owing to the presence of numerous pharmaceutical and biotechnology firms, an expanding number of HIV-related clinical pipelines, and significant R&D expenditure. The availability of state-of-the-art research facilities and growing focus on public health initiatives ensure sustained clinical trial activity in the country.
• In Europe, the HIV clinical trials market is being shaped by increasing collaborations between public and private organizations, favorable governmental policies, and an expanding network of clinical research institutions. The presence of major industry players and advancements in trial technologies also support the region’s steady growth.
• The Asia Pacific region is projected to register the fastest CAGR of 7.63% during the forecast period. Key factors contributing to this rapid expansion include the region’s cost-efficiency for conducting trials, favorable outsourcing trends among global biopharmaceutical companies, a growing burden of chronic diseases including HIV, and ongoing improvements in clinical trial infrastructure. Countries such as India, China, and South Korea are emerging as attractive destinations for clinical trials due to streamlined regulations and access to large patient pools.

Order a free sample PDF of the HIV Clinical Trials Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 1.56 Billion
• 2030 Projected Market Size: USD 2.11 Billion
• CAGR (2025-2030): 5.8%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights

The market players operating across the HIV Clinical Trials are seeking to enhance their customer base, production capacities, and market presence with the adoption of in-organic strategic initiatives such as service launches, partnerships & agreements, expansions, mergers & acquisitions, and others to increase market presence & revenue and gain a competitive edge drives the market growth. Hence, a rising number of strategic initiatives are expected to boost the market share of prominent players operating across the market. For instance, in June 2023, American Gene Technologies launched its new Addimmune company to develop gene & cell therapy technologies to cure HIV. The company will focus on advancing an HIV cure that led to a successful Phase 1 HIV gene & cell therapy clinical trial.

Key Players

• PPD Inc.
• IQVIA Inc.
• Parexel International Corporation
• ICON plc
• Syneos Health
• WuXi AppTec
• Janssen Global Services, LLC
• Gilead Sciences, Inc.
• Bionor Holding AS
• Charles River Laboratories
• GSK plc.
• SGS SA

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The global HIV clinical trials market is set for substantial growth, driven by rising R&D investments, new drug approvals, and the urgent need for improved treatment strategies. Innovations in long-acting therapies, preventive solutions, and precision medicine are transforming the clinical landscape. With North America leading in research capacity and Asia Pacific emerging as a cost-effective hub, global participation is expanding. Pharmaceutical companies remain central to this momentum through ongoing innovation and strategic collaborations. As access improves and trials become more inclusive, the HIV clinical trials market is poised to play a pivotal role in advancing global efforts to manage and ultimately cure HIV.